real-time news and commentary for investors
Wednesday, Sep 11
Wedbush upbeat on SL-401, starts Stemline at Outperform
- Wedbush starts Stemline Therapeutics (STML) at Outperform.
- Analyst David Nierengarten likes SL-401 — which scored an Orphan Drug designation for blastic plasmacytoid dendritic cell neoplasm back in June — saying the targeted diphtheria toxin fusion protein could see regulatory approval "as early as year-end 2015."
- Nierengarten highlights the results from a Phase I/II BPDCN trial and notes that a Phase 2 study is set to begin in H1 2014.
- Price target is $49 representing a 34% upside from today's close.